Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI

Denali Therapeutics

Denali Therapeutics patent portfolio — 42 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
Status
Public
HQ
161 Oyster Point Blvd, South San Francisco, California 94080, US
Founded
2015
Employees
567
Programs
23
Drugs
10
Patents
42
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Denali Therapeutics patents

42 pharmaceutical patents indexed for Denali Therapeutics. 0 expire within 24 months.

Denali Therapeutics has 42 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

42 patents

Patent portfolio

  1. US 12378540

    Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12358928

    Compounds, compositions and methods

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12358896

    LRRK2 inhibitors and methods of making and using thereof

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12240902

    Anti-TREM2 antibodies and methods of use thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12180211

    Compounds, compositions and methods

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12162948

    Methods of engineering transferrin receptor binding polypeptides

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12129263

    Kinase inhibitors and uses thereof

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11999750

    Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11958840

    Compounds, compositions and methods

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11912778

    Methods of engineering transferrin receptor binding polypeptides

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11884944

    Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11866742

    Fusion proteins comprising enzyme replacement therapy enzymes

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11851440

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11851433

    Compounds, compositions and methods

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11834439

    Compounds, compositions, and methods

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11795232

    Engineered transferrin receptor binding polypeptides

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11773185

    Anti-BACE1 antibodies and methods of use thereof

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11661461

    Phospho-Rab antibodies, assays and methods of use thereof

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11643446

    Progranulin variants

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11591316

    Compounds, compositions, and methods

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11427571

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11370832

    Anti-Tau antibodies and methods of use thereof

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11306077

    Compounds, compositions and methods

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11236100

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11214565

    Compound, compositions, and methods

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11203600

    Kinase inhibitors and uses thereof

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11174262

    Compounds, compositions and methods

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11124567

    Anti-TREM2 antibodies and methods of use thereof

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11111235

    Compounds, compositions, and methods

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11072618

    Compounds, compositions and methods

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10870837

    Fusion proteins comprising enzyme replacement therapy enzymes

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10851088

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10709692

    Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10604535

    Compounds, compositions and methods

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10590114

    Compounds, compositions, and methods

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10370361

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10131676

    Compounds, compositions and methods

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9932325

    Compounds, compositions, and methods

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9896458

    Compounds, compositions and methods

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9815850

    Compounds, compositions and methods

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9802927

    Oxadiazine compounds and methods of use thereof

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8591964

    Vaccinium species compositions

    Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Denali Therapeutics have?

42 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Denali Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.